CoChat

Ways into Understanding HIF Inhibition

Open access
Schönberger, Tina, Fandrey, Joachim, Prost-Fingerle, Katrin · 2021 · Cancers
Cited by 38

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Abstract

Hypoxia is a key characteristic of tumor tissue. Cancer cells adapt to low oxygen by activating hypoxia-inducible factors (HIFs), ensuring their survival and continued growth despite this hostile environment. Therefore, the inhibition of HIFs and their target genes is a promising and emerging field of cancer research. Several drug candidates target protein–protein interactions or transcription mechanisms of the HIF pathway in order to interfere with activation of this pathway, which is deregulated in a wide range of solid and liquid cancers. Although some inhibitors are already in clinical trials, open questions remain with respect to their modes of action. New imaging technologies using luminescent and fluorescent methods or nanobodies to complement widely used approaches such as chromatin immunoprecipitation may help to answer some of these questions. In this review, we aim to summarize current inhibitor classes targeting the HIF pathway and to provide an overview of in vitro and in vivo techniques that could improve the understanding of inhibitor mechanisms. Unravelling the distinct principles regarding how inhibitors work is an indispensable step for efficient clinical applications and safety of anticancer compounds.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers13010159

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 39 references

Research works printed but not linked: 93

  1. Semenza, 1992, A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation, Mol. Cell. Biol., 12, 5447
  2. Greijer, 2005, Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1), J. Pathol. A J. Pathol. Soc. G. B. Irel., 206, 291
  3. Yamashita, 2008, Abnormal heart development and lung remodeling in mice lacking the hypoxia-inducible factor-related basic helix-loop-helix PAS protein NEPAS, Mol. Cell. Biol., 28, 1285, 10.1128/MCB.01332-07 · DOI · Paper page
  4. Tanaka, 2009, The human HIF (hypoxia-inducible factor)-3 α gene is a HIF-1 target gene and may modulate hypoxic gene induction, Biochem. J., 424, 143, 10.1042/BJ20090120 · DOI · Paper page
  5. Zhang, 2014, Hypoxia-inducible factor 3 is an oxygen-dependent transcription activator and regulates a distinct transcriptional response to hypoxia, Cell Rep., 6, 1110, 10.1016/j.celrep.2014.02.011 · DOI · Paper page
  6. Schofield, 2005, Signalling hypoxia by HIF hydroxylases, Biochem. Biophys. Res. Commun., 338, 617, 10.1016/j.bbrc.2005.08.111 · DOI · Paper page
  7. Fandrey, 2006, Regulating cellular oxygen sensing by hydroxylation, Cardiovasc. Res., 71, 642, 10.1016/j.cardiores.2006.05.005 · DOI · Paper page
  8. Bruick, 2001, A conserved family of prolyl-4-hydroxylases that modify HIF, Science, 294, 1337, 10.1126/science.1066373 · DOI · Paper page
  9. Watts, 2019, Inflammation and hypoxia: HIF and PHD isoform selectivity, Trends Mol. Med., 25, 33, 10.1016/j.molmed.2018.10.006 · DOI · Paper page
  10. Maxwell, 1993, Inducible operation of the erythropoietin 3’ enhancer in multiple cell lines: Evidence for a widespread oxygen-sensing mechanism, Proc. Natl. Acad. Sci. USA, 90, 2423, 10.1073/pnas.90.6.2423 · DOI · Paper page
  11. Paltoglou, 2007, HIF-1 α and EPAS ubiquitination mediated by the VHL tumour suppressor involves flexibility in the ubiquitination mechanism, similar to other RING E3 ligases, Oncogene, 26, 604, 10.1038/sj.onc.1209818 · DOI
  12. Wang, 1995, Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension, Proc. Natl. Acad. Sci. USA, 92, 5510, 10.1073/pnas.92.12.5510 · DOI · Paper page
  13. Hanahan, 2011, Hallmarks of cancer: The next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
  14. Haddad, 2001, A non-hypoxic, ROS-sensitive pathway mediates TNF-α-dependent regulation of HIF-1α, FEBS Lett., 505, 269, 10.1016/S0014-5793(01)02833-2 · DOI · Paper page
  15. Acker, 2006, The good, the bad and the ugly in oxygen-sensing: ROS, cytochromes and prolyl-hydroxylases, Cardiovasc. Res., 71, 195, 10.1016/j.cardiores.2006.04.008 · DOI · Paper page
  16. Semenza, 2003, Targeting HIF-1 for cancer therapy, Nat. Rev. Cancer, 3, 721, 10.1038/nrc1187 · DOI · Paper page
  17. Wang, 2005, Differential gene up-regulation by hypoxia-inducible factor-1α and hypoxia-inducible factor-2α in HEK293T cells, Cancer Res., 65, 3299, 10.1158/0008-5472.CAN-04-4130 · DOI · Paper page
  18. Harris, 2002, Hypoxia—A key regulatory factor in tumour growth, Nat. Rev. Cancer, 2, 38, 10.1038/nrc704 · DOI · Paper page
  19. Liao, 2007, Hypoxia: A key regulator of angiogenesis in cancer, Cancer Metastasis Rev., 26, 281, 10.1007/s10555-007-9066-y · DOI · Paper page
  20. Zhou, 2018, HIF-3α Promotes Metastatic Phenotypes in Pancreatic Cancer by Transcriptional Regulation of the RhoC–ROCK1 Signaling Pathway, Mol. Cancer Res., 16, 124, 10.1158/1541-7786.MCR-17-0256 · DOI · Paper page
  21. Joharapurkar, 2018, Prolyl hydroxylase inhibitors: A breakthrough in the therapy of anemia associated with chronic diseases, J. Med. Chem., 61, 6964, 10.1021/acs.jmedchem.7b01686 · DOI · Paper page
  22. Dhillon, 2019, Roxadustat: First global approval, Drugs, 79, 563, 10.1007/s40265-019-01077-1 · DOI · Paper page
  23. Sakashita, 2019, Hypoxia-inducible factor-prolyl hydroxylase domain inhibitors to treat anemia in chronic kidney disease, CKD-Associated Complications: Progress in the Last Half Century, Volume 198, 112
  24. Kim, 2015, NNC 55-0396, a T-type Ca 2+ channel inhibitor, inhibits angiogenesis via suppression of hypoxia-inducible factor-1α signal transduction, J. Mol. Med., 93, 499, 10.1007/s00109-014-1235-1 · DOI
  25. Zhu, 2017, Inhibition of HIF-1α by PX-478 suppresses tumor growth of esophageal squamous cell cancer in vitro and in vivo, Am. J. Cancer Res., 7, 1198
  26. Hideshima, 2003, Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341, Blood J. Am. Soc. Hematol., 101, 1530
  27. Kane, 2003, Velcade®: US FDA approval for the treatment of multiple myeloma progressing on prior therapy, Oncologist, 8, 508, 10.1634/theoncologist.8-6-508 · DOI · Paper page
  28. Winning, 2010, Acute hypoxia induces HIF-independent monocyte adhesion to endothelial cells through increased intercellular adhesion molecule-1 expression: The role of hypoxic inhibition of prolyl hydroxylase activity for the induction of NF-κB, J. Immunol., 185, 1786, 10.4049/jimmunol.0903244 · DOI
  29. Huang, 2015, Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis, Oncotarget, 6, 18590, 10.18632/oncotarget.4068 · DOI
  30. Oh, 2015, The histone methyltransferase inhibitor BIX01294 inhibits HIF-1α stability and angiogenesis, Mol. Cells, 38, 528, 10.14348/molcells.2015.0026 · DOI
  31. Park, 2017, Molecular and functional evaluation of a novel HIF inhibitor, benzopyranyl 1, 2, 3-triazole compound, Oncotarget, 8, 7801, 10.18632/oncotarget.13955 · DOI
  32. Lee, 2017, Synthesis and biological evaluation of kresoxim-methyl analogues as novel inhibitors of hypoxia-inducible factor (HIF)-1 accumulation in cancer cells, Bioorg. Med. Chem. Lett., 27, 3026, 10.1016/j.bmcl.2017.05.024 · DOI
  33. Pham, 2015, Translational impact of nanoparticle–drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer, Clin. Cancer Res., 21, 808, 10.1158/1078-0432.CCR-14-2810 · DOI · Paper page
  34. Esteller, 2007, Cancer epigenomics: DNA methylomes and histone-modification maps, Nat. Rev. Genet., 8, 286, 10.1038/nrg2005 · DOI · Paper page
  35. Jones, 2007, The epigenomics of cancer, Cell, 128, 683, 10.1016/j.cell.2007.01.029 · DOI · Paper page
  36. Berdasco, 2010, Aberrant epigenetic landscape in cancer: How cellular identity goes awry, Dev. Cell, 19, 698, 10.1016/j.devcel.2010.10.005 · DOI · Paper page
  37. Mann, 2007, Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma, Clin. Cancer Res., 13, 2318, 10.1158/1078-0432.CCR-06-2672 · DOI · Paper page
  38. Prince, 2012, Romidepsin for cutaneous T-cell lymphoma, Clin. Cancer Res., 18, 3509, 10.1158/1078-0432.CCR-11-3144 · DOI
  39. Poole, 2014, Belinostat: First global approval, Drugs, 74, 1543, 10.1007/s40265-014-0275-8 · DOI · Paper page
  40. Cheng, 2015, Panobinostat, a pan-histone deacetylase inhibitor: Rationale for and application to treatment of multiple myeloma, Drugs Today (Barc. Spain), 51, 491, 10.1358/dot.2015.51.8.2362311 · DOI · Paper page
  41. Pojani, E., and Barlocco, D. (2020). Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy. Curr. Med. Chem. · DOI
  42. Emerit, 2004, Neurodegenerative diseases and oxidative stress, Biomed. Pharmacother., 58, 39, 10.1016/j.biopha.2003.11.004 · DOI · Paper page
  43. Camelo, 2005, Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis, J. Neuroimmunol., 164, 10, 10.1016/j.jneuroim.2005.02.022 · DOI · Paper page
  44. Karuppagounder, 2020, The drug adaptaquin blocks ATF4/CHOP-dependent pro-death Trib3 induction and protects in cellular and mouse models of Parkinson’s disease, Neurobiol. Dis., 136, 104725, 10.1016/j.nbd.2019.104725 · DOI
  45. Alim, 2019, Selenium drives a transcriptional adaptive program to block ferroptosis and treat stroke, Cell, 177, 1262, 10.1016/j.cell.2019.03.032 · DOI · Paper page
  46. Ryu, 2003, Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway, Proc. Natl. Acad. Sci. USA, 100, 4281, 10.1073/pnas.0737363100 · DOI · Paper page
  47. Rroji, 2020, Epigenetic regulators of neuronal ferroptosis identify novel therapeutics for neurological diseases: HDACs, transglutaminases, and HIF prolyl hydroxylases, Neurobiol. Dis., 147, 105145, 10.1016/j.nbd.2020.105145 · DOI
  48. Kim, 2015, Tetrathiomolybdate inhibits mitochondrial complex IV and mediates degradation of hypoxia-inducible factor-1α in cancer cells, Sci. Rep., 5, 14296, 10.1038/srep14296 · DOI
  49. Rose, 2011, Inhibition of 2-oxoglutarate dependent oxygenases, Chem. Soc. Rev., 40, 4364, 10.1039/c0cs00203h · DOI · Paper page
  50. Sun, 2018, Exploring the inhibition mechanism on HIF-2 by inhibitor PT2399 and 0X3 using molecular dynamics simulations, J. Mol. Recognit., 31, e2730, 10.1002/jmr.2730 · DOI
  51. Dekker, 2009, Histone acetyl transferases as emerging drug targets, Drug Discov. Today, 14, 942, 10.1016/j.drudis.2009.06.008 · DOI · Paper page
  52. Delvecchio, 2013, Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation, Nat. Struct. Mol. Biol., 20, 1040, 10.1038/nsmb.2642 · DOI · Paper page
  53. He, Z.-X., Wei, B.-F., Zhang, X., Gong, Y.-P., Ma, L.-Y., and Zhao, W. (2020). Current development of CBP/p300 inhibitors in the last decade. Eur. J. Med. Chem., 112861. · DOI · Paper page
  54. Knurowski, 2019, An Open-Label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477, a First in Clinic Inhibitor of the p300/CPB Bromodomains, As Monotherapy in Patients with Advanced Haematological Malignancies, Blood, 134, 1266, 10.1182/blood-2019-124797 · doi:10.1182/blood-2019-124797
  55. Imayoshi, 2017, CG13250, a novel bromodomain inhibitor, suppresses proliferation of multiple myeloma cells in an orthotopic mouse model, Biochem. Biophys. Res. Commun., 484, 262, 10.1016/j.bbrc.2017.01.088 · DOI
  56. Zhang, 2020, Discovery of novel CBP bromodomain inhibitors through TR-FRET-based high-throughput screening, Acta Pharmacol. Sin., 41, 286, 10.1038/s41401-019-0256-2 · DOI
  57. Jubb, 2004, Expression of vascular endothelial growth factor, hypoxia inducible factor 1α, and carbonic anhydrase IX in human tumours, J. Clin. Pathol., 57, 504, 10.1136/jcp.2003.012963 · DOI · Paper page
  58. Escudier, 2007, Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial, Lancet, 370, 2103, 10.1016/S0140-6736(07)61904-7 · DOI · Paper page
  59. Motzer, 2007, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N. Engl. J. Med., 356, 115, 10.1056/NEJMoa065044 · DOI · Paper page
  60. Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N. Engl. J. Med., 356, 125, 10.1056/NEJMoa060655 · DOI · Paper page
  61. Hua, 2019, Targeting mTOR for cancer therapy, J. Hematol. Oncol., 12, 71, 10.1186/s13045-019-0754-1 · DOI · Paper page
  62. Jafari, 2014, The cellular thermal shift assay for evaluating drug target interactions in cells, Nat. Protoc., 9, 2100, 10.1038/nprot.2014.138 · DOI · Paper page
  63. 1948, Zwischenmolekulare Energiewanderung und Fluoreszenz, Ann. Phys., 437, 55, 10.1002/andp.19484370105 · DOI · Paper page
  64. Lakowicz, 2009, Modification of single molecule fluorescence near metallic nanostructures, Laser Photonics Rev., 3, 221, 10.1002/lpor.200810035 · doi:10.1002/lpor.200810035
  65. Bastiaens, 1999, Fluorescence lifetime imaging microscopy: Spatial resolution of biochemical processes in the cell, Trends Cell Biol., 9, 48, 10.1016/S0962-8924(98)01410-X · DOI · Paper page
  66. Majoul, 2002, Fluorescence resonance energy transfer analysis of protein–protein interactions in single living cells by multifocal multiphoton microscopy, Rev. Mol. Biotechnol., 82, 267, 10.1016/S1389-0352(01)00042-3 · DOI
  67. Clayton, 2004, Graphical representation and multicomponent analysis of single-frequency fluorescence lifetime imaging microscopy data, J. Microsc., 213, 1, 10.1111/j.1365-2818.2004.01265.x · DOI · Paper page
  68. Wotzlaw, 2004, Visualization of the three-dimensional organization of hypoxia-inducible factor-1 alpha and interacting cofactors in subnuclear structures, Biol. Chem., 385, 231
  69. Wotzlaw, 2007, Optical analysis of the HIF-1 complex in living cells by FRET and FRAP, FASEB J., 21, 700, 10.1096/fj.06-6280com · DOI
  70. Frede, 2008, Imaging of the hypoxia-inducible factor pathway: Insights into oxygen sensing, Eur. Respir. J., 32, 210, 10.1183/09031936.00013408 · DOI
  71. Konietzny, 2009, Molecular Imaging: Into In Vivo Interaction of HIF-1α and HIF-2α with ARNT, Ann. N. Y. Acad. Sci., 1177, 74, 10.1111/j.1749-6632.2009.05029.x · DOI
  72. Hoffmann, 2017, Optical analysis of cellular oxygen sensing, Exp. Cell Res., 356, 122, 10.1016/j.yexcr.2017.03.009 · DOI
  73. Frangioni, 2003, In vivo near-infrared fluorescence imaging, Curr. Opin. Chem. Biol., 7, 626, 10.1016/j.cbpa.2003.08.007 · DOI · Paper page
  74. Iglesias, 2009, A novel BRET-based genetically encoded biosensor for functional imaging of hypoxia, Biosens. Bioelectron., 24, 3126, 10.1016/j.bios.2009.04.013 · DOI
  75. Kuchimaru, 2016, A novel injectable BRET-based in vivo imaging probe for detecting the activity of hypoxia-inducible factor regulated by the ubiquitin-proteasome system, Sci. Rep., 6, 34311, 10.1038/srep34311 · DOI
  76. Xiong, 2012, Self-luminescing BRET-FRET near-infrared dots for in vivo lymph-node mapping and tumour imaging, Nat. Commun., 3, 1193, 10.1038/ncomms2197 · DOI · Paper page
  77. Nikooharf, 2020, Development of a Recombinant Monospecific Anti-PLGF Bivalent Nanobody and Evaluation of it in Angiogenesis Modulation, Mol. Biotechnol., 62, 580, 10.1007/s12033-020-00275-7 · DOI
  78. Campochiaro, 2015, Molecular pathogenesis of retinal and choroidal vascular diseases, Prog. Retin. Eye Res., 49, 67, 10.1016/j.preteyeres.2015.06.002 · DOI · Paper page
  79. Stumpf, C., Wimmer, T., Lorenz, B., and Stieger, K. (2020). Creation of different bioluminescence resonance energy transfer based biosensors with high affinity to VEGF. PLoS ONE, 15. · DOI
  80. Robers, 2015, Target engagement and drug residence time can be observed in living cells with BRET, Nat. Commun., 6, 1, 10.1038/ncomms10091 · DOI · Paper page
  81. Kuo, 1999, In Vivo Cross-Linking and Immunoprecipitation for Studying Dynamic Protein: DNA Associations in a Chromatin Environment, Methods, 19, 425, 10.1006/meth.1999.0879 · DOI · Paper page
  82. Orlando, 2000, Mapping chromosomal proteins in vivo by formaldehyde-crosslinked-chromatin immunoprecipitation, Trends Biochem. Sci., 25, 99, 10.1016/S0968-0004(99)01535-2 · DOI · Paper page
  83. Turner, 2003, Immunoprecipitation of native chromatin: NChIP, Methods, 31, 76, 10.1016/S1046-2023(03)00090-2 · DOI · Paper page
  84. Collas, 2010, The current state of chromatin immunoprecipitation, Mol. Biotechnol., 45, 87, 10.1007/s12033-009-9239-8 · DOI · Paper page
  85. Dolk, 2005, Induced refolding of a temperature denatured llama heavy-chain antibody fragment by its antigen, Proteins Struct. Funct. Bioinform., 59, 555, 10.1002/prot.20378 · DOI
  86. Hu, 2017, Nanobody-based delivery systems for diagnosis and targeted tumor therapy, Front. Immunol., 8, 1442, 10.3389/fimmu.2017.01442 · DOI · Paper page
  87. Chanier, T., and Chames, P. (2019). Nanobody engineering: Toward next generation immunotherapies and immunoimaging of cancer. Antibodies, 8. · DOI
  88. Schoonooghe, 2012, Novel applications of nanobodies for in vivo bio-imaging of inflamed tissues in inflammatory diseases and cancer, Immunobiology, 217, 1266, 10.1016/j.imbio.2012.07.009 · DOI
  89. Krasniqi, 2017, Theranostic radiolabeled anti-CD20 sdAb for targeted radionuclide therapy of non-Hodgkin lymphoma, Mol. Cancer Ther., 16, 2828, 10.1158/1535-7163.MCT-17-0554 · DOI
  90. Warnders, 2017, Human epidermal growth factor receptor 3–specific tumor uptake and biodistribution of 89Zr-MSB0010853 visualized by real-time and noninvasive PET imaging, J. Nucl. Med., 58, 1210, 10.2967/jnumed.116.181586 · DOI
  91. Balhuizen, 2017, A nanobody-based tracer targeting DPP6 for non-invasive imaging of human pancreatic endocrine cells, Sci. Rep., 7, 1, 10.1038/s41598-017-15417-2 · DOI
  92. Massa, 2016, Sortase A-mediated site-specific labeling of camelid single-domain antibody-fragments: A versatile strategy for multiple molecular imaging modalities, Contrast Media Mol. Imaging, 11, 328, 10.1002/cmmi.1696 · DOI
  93. Mann, 2019, Nanobody-Conjugated Nanotubes for Targeted Near-Infrared In Vivo Imaging and Sensing, Angew. Chem. Int. Ed., 58, 11469, 10.1002/anie.201904167 · DOI

Cited by

See all 38

Metadata

Authors
Schönberger, T., Fandrey, J., & Prost-Fingerle, K.
Venue
Cancers
Publisher
MDPI AG
Published
2021-01-05
Volume
13
Issue
1
Pages
159
ISSN
2072-6694 (ISSN-L)
OpenAlex
W3118574324
Cited by
38
References
39
FWCI
2.47
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ways into Understanding HIF Inhibition. https://app.cochat.ai/papers/10.3390/cancers13010159
The paper
Schönberger, T., Fandrey, J., & Prost-Fingerle, K. (2021). Ways into Understanding HIF Inhibition. Cancers. https://doi.org/10.3390/cancers13010159

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.